Replies to post #153084 on Biotech Values

[oc631]

GT3 SVR12 rate was 61% (60/98)

This number was butt ugly and should have been the story of the day. Instead newswires gushed praise on GILD's success using the GT2/GT3 combined data. As pointed out the intolerant group might be somewhat more difficult to treat, as opposed to naive patients, in GT3. However a 61% SVR rate is borderline stat sig. in this subgroup.


Some could make a bullish case for GILD's shortcoming in GT3. Since there's little to no developer competition in the GT2/GT3 subgroups GILD could squeak by with sub-par SVR rates in GT3 and then profit once again retreating failures with a three drug combo at a later date.